VIMPAT® (lacosamide) Patent Survives IPR Challenge April 25, 2017 The PTAB upheld the validity of Patent RE38,551 E (“the ’551 patent”), which covers VIMPAT® (lacosamide). See PTAB Litigation Blog by Jones Day, LLP: “Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound” IPR2016-00204 Share: Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Click to share on LinkedIn (Opens in new window) LinkedIn Click to print (Opens in new window) Print
